Evidence map›Paper›PMID 30661045›Full record

ArticleBMJ case reports2019

Hypokalaemic metabolic alkalosis, hypertension and diabetes: what is the link.

Marius Vögelin, Richard Cathomas, Niklaus Kamber, Thomas Fehr

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Marius VögelinDepartment of Internal Medicine, Kantonsspital Graubunden, Chur, Switzerland.
Richard CathomasDepartment of Internal Medicine, Division of Oncology, Kantonsspital Graubunden, Chur, Switzerland.
Niklaus KamberDepartment of Internal Medicine, Division of Endocrinology, Kantonsspital Graubunden, Chur, Switzerland.
Thomas FehrDepartment of Internal Medicine, Kantonsspital Graubunden, Chur, Switzerland.
Kantonsspital Graubünden · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two years after diagnosis of a metastatic neuroendocrine gastrin-secreting tumour and after several cycles of chemotherapy and peptide receptor radionuclide therapy, a 56-year-old woman presented with hypokalaemic metabolic alkalosis, hypertension, leg oedema and new-onset diabetes mellitus. Further investigations revealed renal potassium loss confirmed by a transtubular potassium gradient of 16, fully suppressed serum aldosterone, but instead highly elevated blood levels of morning cortisol and adrenocorticotropic hormone as well as increased urinary excretion of glucocorticoid and mineralocorticoid metabolites. Ruling out other causes, paraneoplastic hypercortisolism was diagnosed. Pharmacological inhibition of the steroid 11β-hydroxylase with metyrapone resulted in complete resolution of metabolic alkalosis, hypokalaemia, hypertension, hyperglycaemia and leg oedema within 1 week.

Indexed as

AlkalosisCushing SyndromeDiabetes MellitusFemaleHumansHypertensionHypokalemiaMetyraponeMiddle AgedSteroid 11-beta-HydroxylaseTreatment OutcomeMetyraponeSteroid 11-beta-Hydroxylasediabetesdrugs: endocrine systemendocrine cancerfluid electrolyte and acid-base disturbanceshypertension

Identifiers

PMID30661045
PMCPMC6340553
OpenAlexW2909078042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.